AbbVie (NYSE:ABBV) Trading 1.9% Higher – Time to Buy?

AbbVie Inc. (NYSE:ABBV)’s stock price was up 1.9% during trading on Thursday . The stock traded as high as $211.45 and last traded at $211.1160. Approximately 4,545,781 shares traded hands during trading, a decline of 39% from the average daily volume of 7,391,874 shares. The stock had previously closed at $207.18.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Company outlook and dividend expectations — Analysts and commentators highlight AbbVie’s strong 2026 guidance and the likelihood of future dividend increases, driven by cash flow from Humira/Imbruvica/oncology and growth in the dermatology portfolio; that narrative supports income investors and dividend yield buyers. AbbVie: Strong 2026 Outlook, Expect Dividend Increases
• Positive Sentiment: Clinical and real‑world data boost dermatology franchise — AbbVie announced new clinical and real‑world evidence for risankizumab (psoriasis/psoriatic arthritis) and upadacitinib (atopic dermatitis), plus Phase‑3 data for vitiligo and alopecia areata to be presented at AAD 2026. Strong safety/efficacy reads can support durable revenue and reduce investor uncertainty around launches. AbbVie to Highlight New Clinical and Real-World Evidence…
• Positive Sentiment: Analyst estimate tweak — Erste Group modestly raised its FY2027 EPS estimate for AbbVie, signaling incremental confidence in earnings power (small change but supportive vs. downside fears). MarketBeat AbbVie Profile
• Neutral Sentiment: Allergan Aesthetics (AbbVie unit) scientific presence — Allergan is presenting multiple evidence‑based posters and product positioning (JUVÉDERM, HA injectables) at AMWC, reinforcing aesthetics growth and brand leadership but with limited immediate revenue impact. Allergan Aesthetics Reinforces Scientific Differentiation…
• Neutral Sentiment: Dividend yield framing for investors — Retail‑focused pieces (The Motley Fool) calculate how many ABBV shares generate targeted dividend income; useful for income investors but not an earnings catalyst. Here’s How Many Shares of AbbVie (ABBV) Stock You’d Need…
• Negative Sentiment: Recent price weakness & value debate — Coverage noting recent share‑price declines and questions about valuation may pressure sentiment in the short term; headline focus on near‑term multiple compression can spur selling even as fundamentals are debated. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Weiss Ratings reiterated a “hold (c)” rating on shares of AbbVie in a research report on Wednesday, January 21st. Piper Sandler raised their price target on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Barclays began coverage on AbbVie in a research note on Thursday, February 19th. They set an “overweight” rating and a $275.00 price target for the company. Evercore lowered their price objective on shares of AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Finally, Royal Bank Of Canada started coverage on shares of AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $253.15.

AbbVie Stock Performance

The business has a fifty day simple moving average of $221.96 and a 200 day simple moving average of $224.52. The stock has a market cap of $370.37 billion, a price-to-earnings ratio of 88.76, a PEG ratio of 0.73 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. The company had revenue of $16.62 billion during the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is 293.22%.

Insider Activity

In other news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Ellenbecker Investment Group raised its stake in AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after purchasing an additional 44 shares during the period. Bank of Jackson Hole Trust grew its stake in shares of AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock valued at $1,648,000 after buying an additional 44 shares during the period. Security National Bank of Sioux City Iowa IA increased its holdings in shares of AbbVie by 0.3% during the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after buying an additional 45 shares during the last quarter. Matthew Goff Investment Advisor LLC increased its holdings in shares of AbbVie by 0.3% during the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after buying an additional 45 shares during the last quarter. Finally, Centennial Wealth Advisory LLC raised its position in shares of AbbVie by 2.2% in the 3rd quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after buying an additional 45 shares during the period. 70.23% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.